Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02781337

Epidemiological and Molecular Colorectal Cancer Registry

This is a Registry that invites patients undergoing colorectal surgery for colorectal cancer. Epidemiological data is collected. The Registry includes tumor tissue and blood banks for analyzing different genetic mutations and disease-specific biomarkers.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–96 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Italiano de Buenos Aires

CABA, Buenos Aires, Argentina

Location status: Recruiting

Location contact

Carlos Vaccaro, MD

PRINCIPAL_INVESTIGATOR

HIBA

CONTACT

54-11-49590200 ext. 8863

María L González, MD

SUB_INVESTIGATOR

Tamara A Piñero, PhD

SUB_INVESTIGATOR

Walter H Pavicic, PhD

SUB_INVESTIGATOR

About this study

This is a Registry that invites patients undergoing colorectal surgery for colorectal cancer. Epidemiological data is collected. The Registry includes tumor tissue and blood samples banks used to studied different genetic variants and disease-specific biomarkers present in patients with Lynch syndrome and others hereditary cancers.

The aim of this registry is to set up the necessary resources to help basic and clinical research projects on colorectal cancer (CRC) within the Hospital Italiano de Buenos Aires (HIBA) and promote scientific collaborations between the HIBA and other institutions within and outside the country.

To make this project, the following specific goals are proposed:

Objective 1: Establishment of an efficient algorithm to enroll patients diagnosed with CRC from HIBA, through collaboration between the services of Surgery, Gastroenterology, Pathology, Oncology, Institute of Translational Medicine and Biomedical Engineering (IMTIB), Medical Clinic and Medical Informatics.

Objective 2: Development of logistics for the connection and expansion of the bank of biological samples (DNA, serum) and tumor samples (tissue fixed in formalin, frozen tissue) to the CRC.

Objective 3: Development of computer software to record data about patient enrolled in a dynamic way.

Objective 4: Development of pipelines and create a supervisory committee to regulate the future of samples and data obtained through the registry, accord the current standards of ethical code, and improve the current collaborations with foreign researchers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients undergoing colorectal surgery for colorectal cancer.

Exclusion criteria

  • Unwillingness to participate.

Treatment and study plan

Primary outcomes

  1. Overall survival

    Time frame: 5 years

    Patient overall survival at 5 years.

  2. Disease-free survival

    Time frame: 5 years

    The time free of disease recurrence will be estimated in the whole cohort and according to colorectal cancer stages and molecular profiles.

Secondary outcomes

  1. Molecular characteristics of colorectal adenocarcinoma.

    At initial diagnosis, molecular tumor markers will be determined in the tissue samples.

Study contacts

Contact information is provided by the study sponsor or research team.

Carlos Vaccaro, MD

CONTACT

[email protected]

María L González, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Hospital Italiano de Buenos Aires

Other

Registry information

Acronym: EMR-CRC

Important dates

Study start
2012
Primary completion
2029
Study completion
2033
First posted
May 24, 2016
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.